PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

NCT01227018 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped interim analysis found the study drug to be ineffective

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: STA-9090
RADIATION: Radiologic imaging
PROCEDURE: blood draw

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]